ストックスクリーナーアプリを入手
21.76
2.90%
-0.65
前日終値:
$22.41
開ける：
$22.2
24時間の取引高:
690.36K
Relative Volume:
0.87
時価総額：
$2.46B
収益：
$14.09M
当期純損益:
$-176.94M
株価収益率:
-10.12
EPS:
-2.15
ネットキャッシュフロー:
$-141.24M
1週間 パフォーマンス:
-8.84%
1か月 パフォーマンス:
+4.07%
6か月 パフォーマンス:
+34.07%
1年 パフォーマンス:
-7.99%
1日の値動き範囲:
$21.55
$22.89
1週間の範囲:
$21.55
$24.51
52週間の値動き範囲:
$15.19
$27.29
Newamsterdam Pharma Company Nv Stock (NAMS) Company Profile
NAMS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NAMS
Newamsterdam Pharma Company Nv
|
21.76 | 2.46B | 14.09M | -176.94M | -141.24M | -2.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Newamsterdam Pharma Company Nv Stock (NAMS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-30 | 開始されました | H.C. Wainwright | Buy |
| 2024-05-15 | 開始されました | TD Cowen | Buy |
| 2024-03-14 | 開始されました | Scotiabank | Sector Outperform |
| 2024-01-18 | 開始されました | Guggenheim | Buy |
| 2024-01-16 | 開始されました | Piper Sandler | Overweight |
| 2023-10-30 | 開始されました | RBC Capital Mkts | Outperform |
すべてを表示
Newamsterdam Pharma Company Nv (NAMS) 最新ニュース
NewAmsterdam Pharma (NASDAQ:NAMS) Shares Acquired by Swiss National Bank - Defense World
Newamsterdam Pharma director James Topper buys $25,520 in shares By Investing.com - Investing.com South Africa
Newamsterdam Pharma CEO Michael Davidson sells shares for $281,000 - Investing.com India
Newamsterdam Pharma director James Topper buys $25,520 in shares - Investing.com India
Newamsterdam pharma COO sells shares worth $376,000 - Investing.com
Newamsterdam Pharma CEO Michael Davidson sells shares for $281,000 By Investing.com - Investing.com UK
Newamsterdam Pharma COO Kling sells $2.36 million in stock By Investing.com - Investing.com Australia
Newamsterdam Pharma COO Kling sells $2.36 million in stock - Investing.com
NewAmsterdam Pharma (NASDAQ:NAMS) Shares Sold by US Bancorp DE - Defense World
NewAmsterdam Pharma (NASDAQ:NAMS) Receives $43.33 Consensus Price Target from Analysts - Defense World
Financial Metrics Exploration: Understanding NewAmsterdam Pharma Company NV (NAMS) Through Ratios - The Dwinnex
9,983 Shares in NewAmsterdam Pharma (NASDAQ:NAMS) Purchased by Keybank National Association OH - Defense World
A better buy-in window may exist right now for NewAmsterdam Pharma Company NV (NAMS) - SETE News
Newamsterdam pharma director James Topper buys $84,203 in shares By Investing.com - Investing.com Australia
Newamsterdam pharma director James Topper buys $84,203 in shares - Investing.com
New Amsterdam Pharma chief accounting officer sells $3.06 million in shares - Investing.com India
New Amsterdam Pharma chief accounting officer sells $3.06 million in shares By Investing.com - Investing.com South Africa
William Blair Has Negative Forecast for NAMS Q1 Earnings - Defense World
NewAmsterdam Pharma (NASDAQ:NAMS) Price Target Raised to $52.00 - Defense World
(NAMS) Pivots Trading Plans and Risk Controls - Stock Traders Daily
NewAmsterdam Pharma: Significant Upside Possible In Case Of Approval Of Obicetrapib - Seeking Alpha
NewAmsterdam Pharma: A Mispriced Bet On A Cholesterol Revolution (NASDAQ:NAMS) - Seeking Alpha
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Yearly Results: Here's What Analysts Are Forecasting For This Year - Yahoo Finance
NewAmsterdam Pharma’s 2024 Financial Results and Clinical Progress - TipRanks
7 Analysts Have This To Say About NewAmsterdam Pharma - Benzinga
Scotiabank raises NewAmsterdam Pharma target to $52 - Investing.com India
Scotiabank raises NewAmsterdam Pharma target to $52 By Investing.com - Investing.com South Africa
Newamsterdam Pharma Faces Potential Investor Risks Due to Shareholder Influence - TipRanks
NewAmsterdam Pharma's Full-Year Net Loss Widens, Revenue Rises -February 26, 2025 at 08:27 am EST - Marketscreener.com
Earnings Flash (NAMS) NewAmsterdam Pharma Posts Full Year 2024 Revenue $45.6M, vs. FactSet Est of $33.8M - Marketscreener.com
NewAmsterdam Pharma Reports Full Year 2024 Financial Results and Provides Corporate Update - The Manila Times
NewAmsterdam Pharma Co N.V. SEC 10-K Report - TradingView
Can NewAmsterdam's Obicetrapib Reshape Cardiovascular Treatment? Phase 3 Results Show 49% LDL-C Reduction - StockTitan
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March - The Manila Times
NewAmsterdam Pharma Company N.V. (NAMS): Among the Oversold Biotech Stocks to Buy Now - Insider Monkey
10 Oversold Biotech Stocks to Buy Now - Insider Monkey
How to Take Advantage of moves in (NAMSW) - Stock Traders Daily
Newamsterdam pharma COO sells shares worth $1.8 million - Investing.com India
Newamsterdam pharma COO sells shares worth $1.8 million By Investing.com - Investing.com Nigeria
How To Trade (NAMS) - Stock Traders Daily
Mirae Asset Global Investments Co. Ltd. Makes New Investment in NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World
Both private equity firms who control a good portion of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) along with institutions must be dismayed after last week's 8.1% decrease - Yahoo Finance
NewAmsterdam Pharma (NASDAQ:NAMS) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Newamsterdam Pharma Company Nv (NAMS) 財務データ
収益
当期純利益
現金流量
EPS
Newamsterdam Pharma Company Nv (NAMS) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Kooij Louise Frederika | Chief Accounting Officer |
Mar 26 '25 |
Option Exercise |
0.00 |
8,269 |
0 |
23,269 |
| LANGE LOUIS G | Director |
Mar 26 '25 |
Option Exercise |
0.00 |
3,102 |
0 |
10,062 |
| Kastelein Johannes Jacob Piete | Chief Scientific Officer |
Mar 26 '25 |
Option Exercise |
0.00 |
45,481 |
0 |
79,481 |
| Kling Douglas F | Chief Operating Officer |
Mar 26 '25 |
Option Exercise |
0.00 |
16,539 |
0 |
60,539 |
| Davidson Michael H. | Chief Executive Officer |
Mar 26 '25 |
Option Exercise |
0.00 |
38,394 |
0 |
402,699 |
0.39%
0.34%
大文字化:
|
ボリューム (24 時間):